Chloe Robins

Age UK — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

13h-index2.4kcitations35works27.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Epigenetics and DNA Methylation(14), Genetic Associations and Epidemiology(13), Bioinformatics and Genomic Networks(9), Alzheimer's disease research and treatments(5), Genomics and Rare Diseases(5)

Publications35 total

Variable information across SNPs in GWAS data can cause false rejections of colocalisation which can be resolved by proportional colocalisation tests
2025· 1 citedOpen Access
Whole-genome sequencing of 490,640 UK Biobank participants
Nature·2025· 47 citedOpen Access
Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures across the Alzheimer disease continuum
Neuron·2025· 35 cited
Patient stratification by genetic risk in Alzheimer’s disease is only effective in the presence of phenotypic heterogeneity
PLoS ONE·2025· 2 citedOpen Access
Genetic evidence supports therapeutic hypothesis of increasing progranulin levels for Alzheimer’s Disease
Alzheimer s & Dementia·2024Open Access
Multi‐cohort cerebrospinal fluid proteomics identifies robust molecular signatures for asymptomatic and symptomatic Alzheimer’s disease
Alzheimer s & Dementia·2024· 1 citedOpen Access
Integration of GWAS and cerebrospinal fluid proteogenomics identifies proteins for AD and shared dysregulated mechanisms in other neurological traits
Alzheimer s & Dementia·2024Open Access
Proteomic signatures improve risk prediction for common and rare diseases
Nature Medicine·2024· 147 citedOpen Access
Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures for asymptomatic and symptomatic Alzheimer’s disease.
2024· 13 citedOpen Access
Plasma proteomic associations with genetics and health in the UK Biobank
Nature·2023· 1.3k citedOpen Access
Proteomic prediction of common and rare diseases
2023· 14 citedOpen Access
Systematic disease-agnostic identification of therapeutically actionable targets using the genetics of human plasma proteins.
2023Open Access
Systematic disease-agnostic identification of therapeutically actionable targets using the genetics of human plasma proteins
2023· 7 citedOpen Access
Identification of novel genetic variants and biomarkers for cognitive decline in Alzheimer’s disease
Alzheimer s & Dementia·2023Open Access
Genetic regulation of the human plasma proteome in 54,306 UK Biobank participants
2022· 128 citedOpen Access
A machine learning approach to brain epigenetic analysis reveals kinases associated with Alzheimer’s disease
Nature Communications·2021· 49 citedOpen Access
Genetic control of the human brain proteome
The American Journal of Human Genetics·2021· 112 citedOpen Access
Brain DNA Methylation Patterns in CLDN5 Associated With Cognitive Decline
Biological Psychiatry·2021· 67 citedOpen Access
Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer’s disease pathogenesis
Nature Genetics·2021· 380 citedOpen Access
Identifying novel causal genes and proteins in Alzheimer’s disease
Alzheimer s & Dementia·2020· 1 cited
page 1 of 2Next →

Frequent Co-authors

Aliza P. Wingo(12), Thomas S. Wingo(12), Philip L. De Jager(11), David A. Bennett(11), Karen N. Conneely(11), Praveen Surendran(7), Robert A. Scott(7), Allan I. Levey(7), David Pulford(7), Jonathan Davitte(6), Duc M. Duong(6), Nicholas T. Seyfried(6), Elizabeth M. Kennedy(6), Ekaterina S. Gerasimov(5), Michael P. Epstein(5), James J. Lah(5), David J. Cutler(5), Divya Mehta(5), Torsten Klengel(5), Eleazar Eskin(5)